The line of modern anticancer drugs is constantly being supplemented with new drugs. Many of them are generics of already known products. For example, the Evermil product, which is produced by one of the Indian pharmaceutical companies, is a complete analogue of the Afinitor drug, which has already had a positive reputation in the treatment of cancer patients. You can buy Evermil 10mg (Everolimus) Evermil (Everolimus) - an analogue of Afinitor to buy in our online pharmacy. Description Evermil is identical in composition to Afinitor. Its therapeutic effect is provided by the same active ingredient - everolimus. Based on the properties of this agent, it can be concluded that the drug Evermil 10 mg refers to inhibitors with a selective effect. Once in the body, this component begins to actively block the growth of tumor cells. A similar effect is exerted on fibroblasts, vascular smooth muscle cells, endothelial structures. All these actions lead to a slowdown in the progression of the pathological process, and this increases the survival period of cancer patients by almost five years. But not only this creates additional chances even for hopeless patients. The fact is that against the background of therapy with the Evermil drug, the very quality of life of such patients is significantly improved. Experts came to this conclusion when they tried to comprehensively assess the impact of negative symptoms on various spheres of life of people suffering from cancer. If you are interested in current onEvermil 10mg (Everolimus) Evermil (Everolimus) - analogue of Afinitor cost - contact the consultant of our pharmacy.
Side effects Of the side reactions that may appear during treatment, it is worth highlighting: • asthenia; • stomatitis; • skin rash, itching; • fatigue; • violations of hematopoiesis; • arterial hypertension; • anorexia; • fast fatigue; • headaches and other negative reactions. The doctor must know about the slightest change in the condition of the patient receiving the drug Evermil
©2020 CopyRight Onco24.com. All rights reserved.